Blood Advances

Article	Citations
American Society of Hematology 2020 guidelines for management of venous thromboembolism: treatment of deep vein thrombosis and pulmonary embolism	619
American Society of Hematology 2021 guidelines for management of venous thromboembolism: prevention and treatment in patients with cancer	412
American Society of Hematology 2021 guidelines on the use of anticoagulation for thromboprophylaxis in patients with COVID-19	302
Real-world evidence of tisagenlecleucel for pediatric acute lymphoblastic leukemia and non-Hodgkin lymphoma	263
ASH ISTH NHF WFH 2021 guidelines on the diagnosis of von Willebrand disease	252
Tumor burden, inflammation, and product attributes determine outcomes of axicabtagene ciloleucel in large B-cell lymphoma	237
Predictive factors of early progression after CAR T-cell therapy in relapsed/refractory diffuse large B-cell lymphoma	223
A neutrophil activation signature predicts critical illness and mortality in COVID-19	221
American Society of Hematology 2020 guidelines for sickle cell disease: prevention, diagnosis, and treatment of cerebrovascular disease in children and adults	203
A large meta-analysis establishes the role of MRD negativity in long-term survival outcomes in patients with multiple myeloma	193
First case of COVID-19 in a patient with multiple myeloma successfully treated with tocilizumab	186
American Society of Hematology 2020 guidelines for sickle cell disease: management of acute and chronic pain	179
Hematopoietic recovery in patients receiving chimeric antigen receptor T-cell therapy for hematologic malignancies	160
ASH ISTH NHF WFH 2021 guidelines on the management of von Willebrand disease	156
High metabolic tumor volume is associated with decreased efficacy of axicabtagene ciloleucel in large B-cell lymphoma	137
Bridging therapy prior to axicabtagene ciloleucel for relapsed/refractory large B-cell lymphoma	131
Molecular mechanisms mediating relapse following ivosidenib monotherapy in IDH1-mutant relapsed or refractory AML	123
A phase 3 randomized study of 5-azacitidine maintenance vs observation after transplant in high-risk AML and MDS patients	122
Efficacy of the BNT162b2 mRNA COVID-19 vaccine in patients with B-cell non-Hodgkin lymphoma	122
Diversity of peripheral blood human NK cells identified by single-cell RNA sequencing	121
Outcomes of patients with hematologic malignancies and COVID-19: a report from the ASH Research Collaborative Data Hub	119
Efficacy and safety of anti-CD19 CAR T-cell therapy in 110 patients with B-cell acute lymphoblastic leukemia with high-risk features	115
The association of ABO blood group with indices of disease severity and multiorgan dysfunction in COVID-19	114
Clinical efficacy of anakinra to mitigate CAR T-cell therapy–associated toxicity in large B-cell lymphoma	113
Benign and malignant hematologic manifestations in patients with VEXAS syndrome due to somatic mutations in UBA1	113

Reduced prevalence of SARS-CoV-2 infection in ABO blood group O	112
American Society of Hematology 2020 guidelines for treating newly diagnosed acute myeloid leukemia in older adults	109
Prognostic and therapeutic impacts of mutant TP53 variant allelic frequency in newly diagnosed acute myeloid leukemia	105
Clinical and molecular predictors of response and survival following venetoclax therapy in relapsed/refractory AML	102
Evidence of thrombotic microangiopathy in children with SARS-CoV-2 across the spectrum of clinical presentations	102
Outcomes of older patients with NPM1-mutated AML: current treatments and the promise of venetoclax-based regimens	101
Dissemination of extreme levels of extracellular vesicles: tissue factor activity in patients with severe COVID-19	96
How much has allogeneic stem cell transplant–related mortality improved since the 1980s? A retrospective analysis from the EBMT	93
Haploidentical BMT for severe aplastic anemia with intensive GVHD prophylaxis including posttransplant cyclophosphamide	93
International evidence-based consensus diagnostic and treatment guidelines for unicentric Castleman disease	92
Immune reconstitution and infectious complications following axicabtagene ciloleucel therapy for large B-cell lymphoma	92
Myelodysplastic syndrome unrelated to lentiviral vector in a patient treated with gene therapy for sickle cell disease	92
Up to 8-year follow-up from RESONATE-2: first-line ibrutinib treatment for patients with chronic lymphocytic leukemia	91
Venetoclax and azacitidine compared with induction chemotherapy for newly diagnosed patients with acute myeloid leukemia	91
Impaired natural killer cell counts and cytolytic activity in patients with severe COVID-19	89
TP53 mutation defines a unique subgroup within complex karyotype de novo and therapy-related MDS/AML	89
Successful allogeneic hematopoietic stem cell transplantation in patients with VEXAS syndrome: a 2-center experience	86
Sustained prothrombotic changes in COVID-19 patients 4 months after hospital discharge	84
TP53 abnormalities correlate with immune infiltration and associate with response to flotetuzumab immunotherapy in AML	84
Real-world data confirm the effectiveness of caplacizumab in acquired thrombotic thrombocytopenic purpura	79
Venetoclax and hypomethylating agents (HMAs) induce high response rates in MDS, including patients after HMA therapy failure	79
Polatuzumab vedotin plus bendamustine and rituximab in relapsed/refractory DLBCL: survival update and new extension cohort data	76
The SARS-CoV-2 receptor-binding domain preferentially recognizes blood group A	76
ACVR1/JAK1/JAK2 inhibitor momelotinib reverses transfusion dependency and suppresses hepcidin in myelofibrosis phase 2 trial	76
The critical role of CD4+ T cells in PD-1 blockade against MHC-II–expressing tumors such as classic Hodgkin lymphoma	75
DLBCL patients treated with CD19 CAR T cells experience a high burden of organ toxicities but low nonrelapse mortality	74
Next-generation cell therapies: the emerging role of CAR-NK cells	74
Young adult outcomes of childhood prophylaxis for severe hemophilia A: results of the Joint Outcome Continuation Study	72
Vaccine response following anti-CD20 therapy: a systematic review and meta-analysis of 905 patients	71
Clinical and radiologic correlates of neurotoxicity after axicabtagene ciloleucel in large B-cell lymphoma	70
Platelet-derived extracellular vesicles infiltrate and modify the bone marrow during inflammation	69
First-line imatinib vs second- and third-generation TKIs for chronic-phase CML: a systematic review and meta-analysis	68
Durable ibrutinib responses in relapsed/refractory marginal zone lymphoma: long-term follow-up and biomarker analysis	67
Clinical outcomes of older patients with AML receiving hypomethylating agents: a large population-based study in the United States	67
Artificial thymic organoids represent a reliable tool to study T-cell differentiation in patients with severe T-cell lymphopenia	67
Teclistamab is an active T cell–redirecting bispecific antibody against B-cell maturation antigen for multiple myeloma	66
A phase 1 trial of itacitinib, a selective JAK1 inhibitor, in patients with acute graft-versus-host disease	66
Follicular lymphoma t(14;18)-negative is genetically a heterogeneous disease	65
LAG3: a novel immune checkpoint expressed by multiple lymphocyte subsets in diffuse large B-cell lymphoma	64
CD19-directed CAR T-cell therapy for treatment of primary CNS lymphoma	63
Genetic mutations and features of mantle cell lymphoma: a systematic review and meta-analysis	63
Delineation of target expression profiles in CD34+/CD38− and CD34+/CD38+ stem and progenitor cells in AML and CML	62
Outcomes in patients with DLBCL treated with commercial CAR T cells compared with alternate therapies	62
Severe cytokine release syndrome is associated with hematologic toxicity following CD19 CAR T-cell therapy	61
Zanubrutinib for the treatment of relapsed or refractory mantle cell lymphoma	61
Posttransplantation MRD monitoring in patients with AML by next-generation sequencing using DTA and non-DTA mutations	61
Survival following allogeneic transplant in patients with myelofibrosis	61
Prognostic impact of CEBPA bZIP domain mutation in acute myeloid leukemia	61
Fatal thrombotic microangiopathy case following adeno-associated viral SMN gene therapy	61
BiTEs better than CAR T cells	60

Zanubrutinib for the treatment of MYD88 wild-type Waldenström macroglobulinemia: a substudy of the phase 3 ASPEN trial	60
Modified EASIX predicts severe cytokine release syndrome and neurotoxicity after chimeric antigen receptor T cells	60
Frequency of venous thromboembolism in 6513 patients with COVID-19: a retrospective study	60
Clonal hematopoiesis in angioimmunoblastic T-cell lymphoma with divergent evolution to myeloid neoplasms	60
Clinical predictors of poor outcomes in patients with sickle cell disease and COVID-19 infection	59
Genetic and evolutionary patterns of treatment resistance in relapsed B-cell lymphoma	59
Determining the recommended dose of pacritinib: results from the PAC203 dose-finding trial in advanced myelofibrosis	58
Impaired T- and NK-cell reconstitution after haploidentical HCT with posttransplant cyclophosphamide	58
CRP and ferritin in addition to the EASIX score predict CAR-T–related toxicity	58
Phase 2 multiple-dose study of an FcRn inhibitor, rozanolixizumab, in patients with primary immune thrombocytopenia	58
Apixaban compared with warfarin to prevent thrombosis in thrombotic antiphospholipid syndrome: a randomized trial	57
Inflammasome activation in neutrophils of patients with severe COVID-19	57
Incidence of symptomatic, image-confirmed venous thromboembolism following hospitalization for COVID-19 with 90-day follow-up	57
Immunogenicity of COVID-19 vaccines in patients with hematologic malignancies: a systematic review and meta-analysis	57
Prognostic value of measurable residual disease after venetoclax and decitabine in acute myeloid leukemia	56
Clinical characteristics and treatment outcomes of newly diagnosed multiple myeloma with chromosome 1q abnormalities	56
Fedratinib in myelofibrosis	55
Real-life experience with CPX-351 and impact on the outcome of high-risk AML patients: a multicentric French cohort	55
Functional and phylogenetic alterations in gut microbiome are linked to graft-versus-host disease severity	55
Building access to care in adult sickle cell disease: defining models of care, essential components, and economic aspects	55
Preclinical activity and determinants of response of the GPRC5DxCD3 bispecific antibody talquetamab in multiple myeloma	55
High-sensitivity C-reactive protein is associated with clonal hematopoiesis of indeterminate potential	54
Polatuzumab vedotin as a salvage and bridging treatment in relapsed or refractory large B-cell lymphomas	54
COVID-19 in individuals with sickle cell disease/trait compared with other Black individuals	54
Clinical activity of axicabtagene ciloleucel in adult patients with Richter syndrome	53
T follicular helper phenotype predicts response to histone deacetylase inhibitors in relapsed/refractory peripheral T-cell lymphoma	53
Mesenchymal stromal cell therapeutic potency is dependent upon viability, route of delivery, and immune match	53
Myeloablative haploidentical BMT with posttransplant cyclophosphamide for hematologic malignancies in children and adults	52
Allogeneic stem cell transplantation for chronic lymphocytic leukemia in the era of novel agents	52
Grading and management of cytokine release syndrome in patients treated with tisagenlecleucel in the JULIET trial	52
Platelet reactivity to thrombin differs between patients with COVID-19 and those with ARDS unrelated to COVID-19	52
The dual PI3Kδ/CK1ε inhibitor umbralisib exhibits unique immunomodulatory effects on CLL T cells	52
Safety and activity of varlilumab, a novel and first-in-class agonist anti-CD27 antibody, for hematologic malignancies	51
In vivo HSPC gene therapy with base editors allows for efficient reactivation of fetal γ-globin in β-YAC mice	50
American Society of Hematology living guidelines on the use of anticoagulation for thromboprophylaxis in patients with COVID-19: July 2021 update on postdischarge thromboprophylaxis	50
Nationwide survey of systemic chronic active EBV infection in Japan in accordance with the new WHO classification	50
Artificial intelligence–based morphological fingerprinting of megakaryocytes: a new tool for assessing disease in MPN patients	50
Added prognostic value of secondary AML-like gene mutations in ELN intermediate-risk older AML: ALFA-1200 study results	49
Preinfusion factors impacting relapse immunophenotype following CD19 CAR T cells	49
Genomic analysis of primary and secondary myelofibrosis redefines the prognostic impact of ASXL1 mutations: a FIM study	48
Comorbidities are risk factors for hospitalization and serious COVID-19 illness in children and adults with sickle cell disease	48
RAS/CBL mutations predict resistance to JAK inhibitors in myelofibrosis and are associated with poor prognostic features	48
Safety and efficacy of rivaroxaban in pediatric cerebral venous thrombosis (EINSTEIN-Jr CVT)	48
The incidence of cancer-associated thrombosis is increasing over time	48
Randomized phase 3 ALCANZA study of brentuximab vedotin vs physician’s choice in cutaneous T-cell lymphoma: final data	47
Quantitative analysis of mRNA-1273 COVID-19 vaccination response in immunocompromised adult hematology patients	47
Autoimmune- and complement-mediated hematologic condition recrudescence following SARS-CoV-2 vaccination	47
A prognostic model to predict survival after 6 months of ruxolitinib in patients with myelofibrosis	47
Clonal hematopoiesis in patients receiving chimeric antigen receptor T-cell therapy	46
Approval of tagraxofusp-erzs for blastic plasmacytoid dendritic cell neoplasm	46
Pevonedistat plus azacitidine vs azacitidine alone in higher-risk MDS/chronic myelomonocytic leukemia or low-blast-percentage AML	46
Influenza-induced thrombocytopenia is dependent on the subtype and sialoglycan receptor and increases with virus pathogenicity	46
Lung megakaryocytes display distinct transcriptional and phenotypic properties	46
Glioblastoma cell populations with distinct oncogenic programs release podoplanin as procoagulant extracellular vesicles	46
A pragmatic multi-institutional approach to understanding transplant-associated thrombotic microangiopathy after stem cell transplant	46
Branched evolution and genomic intratumor heterogeneity in the pathogenesis of cutaneous T-cell lymphoma	46
COVID-19 coagulopathy vs disseminated intravascular coagulation	45
Geriatric assessment in older alloHCT recipients: association of functional and cognitive impairment with outcomes	45
Infectious complications in patients with relapsed refractory multiple myeloma after BCMA CAR T-cell therapy	45
Optimal fludarabine lymphodepletion is associated with improved outcomes after CAR T-cell therapy	45
Inducible MyD88/CD40 synergizes with IL-15 to enhance antitumor efficacy of CAR-NK cells	44
Posttransplant cyclophosphamide for prevention of graft-versus-host disease: results of the prospective randomized HOVON-96 trial	44
COVID-19 and CAR T cells: a report on current challenges and future directions from the EPICOVIDEHA survey by EHA-IDWP	44
Correction of β-thalassemia by CRISPR/Cas9 editing of the α-globin locus in human hematopoietic stem cells	44
Blastic plasmacytoid dendritic cell neoplasms: results of an international survey on 398 adult patients	43
Human GATA2 mutations and hematologic disease: how many paths to pathogenesis?	43
Genomic heterogeneity in core-binding factor acute myeloid leukemia and its clinical implication	43
CD19 antibody-drug conjugate therapy in DLBCL does not preclude subsequent responses to CD19-directed CAR T-cell therapy	43
ADAMTS13 and VWF activities guide individualized caplacizumab treatment in patients with aTTP	43
American Society of Hematology living guidelines on the use of anticoagulation for thromboprophylaxis in patients with COVID-19: May 2021 update on the use of intermediate-intensity anticoagulation in	43
Phase 2 study of ruxolitinib and decitabine in patients with myeloproliferative neoplasm in accelerated and blast phase	43
Prebiotics protect against acute graft-versus-host disease and preserve the gut microbiota in stem cell transplantation	42
A phase 2 study of ATRA, arsenic trioxide, and gemtuzumab ozogamicin in patients with high-risk APL (SWOG 0535)	42
Associations of the gut microbiome and clinical factors with acute GVHD in allogeneic HSCT recipients	42
Comparison of 2-year outcomes with CAR T cells (ZUMA-1) vs salvage chemotherapy in refractory large B-cell lymphoma	42
A randomized phase 2 trial of azacitidine with or without durvalumab as first-line therapy for older patients with AML	42
Cell interactions in the bone marrow microenvironment affecting myeloid malignancies	42
Neutrophil extracellular traps and inflammasomes cooperatively promote venous thrombosis in mice	41
Prevalence, predictors, and outcomes of clonal hematopoiesis in individuals aged ≥80 years	41
Dynamic angiopoietin-2 assessment predicts survival and chronic course in hospitalized patients with COVID-19	41

Phase 2 study of venetoclax plus carfilzomib and dexamethasone in patients with relapsed/refractory multiple myeloma	41
Baseline and serial molecular profiling predicts outcomes with hypomethylating agents in myelodysplastic syndromes	41
Outcomes of patients with CLL sequentially resistant to both BCL2 and BTK inhibition	40
Lingering effects of chemotherapy on mature T cells impair proliferation	40
Humoral immune reconstitution after anti-BCMA CAR T-cell therapy in relapsed/refractory multiple myeloma	40
Anti-CD19 CAR T cells in combination with ibrutinib for the treatment of chronic lymphocytic leukemia	40
Optimal timing and criteria of interim PET in DLBCL: a comparative study of 1692 patients	40
Application of machine learning in the management of acute myeloid leukemia: current practice and future prospects	40
CAR T-cell therapy for secondary CNS DLBCL	40
The immunomodulatory drugs lenalidomide and pomalidomide enhance the potency of AMG 701 in multiple myeloma preclinical models	40
Cellular and humoral immunogenicity of the mRNA-1273 SARS-CoV-2 vaccine in patients with hematologic malignancies	40
Development of luspatercept to treat ineffective erythropoiesis	40
American Society of Hematology living guidelines on the use of anticoagulation for thromboprophylaxis in patients with COVID-19: January 2022 update on the use of therapeutic-intensity anticoagulation	39
Systematic review and meta-analysis of test accuracy for the diagnosis of suspected pulmonary embolism	39
Poor neutralizing antibody responses in 106 patients with WM after vaccination against SARS-CoV-2: a prospective study	39
Predictors of preprocedural direct oral anticoagulant levels in patients having an elective surgery or procedure	39
Caplacizumab prevents refractoriness and mortality in acquired thrombotic thrombocytopenic purpura: integrated analysis	39
First-in-human phase 1 trial of induced regulatory T cells for graft-versus-host disease prophylaxis in HLA-matched siblings	39
Pooled safety analysis of zanubrutinib monotherapy in patients with B-cell malignancies	39
KEYNOTE-013 4-year follow-up of pembrolizumab in classical Hodgkin lymphoma after brentuximab vedotin failure	38
Phase 1 study of CWP232291 in patients with relapsed or refractory acute myeloid leukemia and myelodysplastic syndrome	38
Humoral response to mRNA anti–COVID-19 vaccines BNT162b2 and mRNA-1273 in patients with chronic lymphocytic leukemia	38
A systematic review of antithrombotic treatment of venous thromboembolism in patients with myeloproliferative neoplasms	38
Laboratory monitoring of hemophilia A treatments: new challenges	38
Patterns of salivary microbiota injury and oral mucositis in recipients of allogeneic hematopoietic stem cell transplantation	38
Erythrocytosis in the general population: clinical characteristics and association with clonal hematopoiesis	38
Comparing transplant outcomes in ALL patients after haploidentical with PTCy or matched unrelated donor transplantation	38
Leukemic evolution of polycythemia vera and essential thrombocythemia: genomic profiles predict time to transformation	38
Mesenchymal stromal cells in hematopoietic cell transplantation	38
High-sensitivity next-generation sequencing MRD assessment in ALL identifies patients at very low risk of relapse	38
High prevalence of clonal hematopoiesis in the blood and bone marrow of healthy volunteers	38
Integrative analysis of a phase 2 trial combining lenalidomide with CHOP in angioimmunoblastic T-cell lymphoma	38
Platelet activation by SARS-CoV-2 implicates the release of active tissue factor by infected cells	38
Relationship of donor age and relationship to outcomes of haploidentical transplantation with posttransplant cyclophosphamide	38
Inflammasome activation promotes venous thrombosis through pyroptosis	37
American Society of Hematology 2021 guidelines for sickle cell disease: stem cell transplantation	37
Large-scale circular RNA deregulation in T-ALL: unlocking unique ectopic expression of molecular subtypes	37
Early FDG-PET response predicts CAR-T failure in large B-cell lymphoma	37
Antitumor activity of the dual BET and CBP/EP300 inhibitor NEO2734	37
A systematic review of quality of life in sickle cell disease and thalassemia after stem cell transplant or gene therapy	37
First-line non–anthracycline-based chemotherapy for extranodal nasal-type NK/T-cell lymphoma: a retrospective analysis from the CLCG	36
Plasminogen activator inhibitor 1 and venous thrombosis in pancreatic cancer	36
Impact of splicing mutations in acute myeloid leukemia treated with hypomethylating agents combined with venetoclax	36
Outcome of patients with IDH1/2-mutated post–myeloproliferative neoplasm AML in the era of IDH inhibitors	36
Flow studies on human GPVI-deficient blood under coagulating and noncoagulating conditions	36
Real-world effectiveness of CPX-351 vs venetoclax and azacitidine in acute myeloid leukemia	36
Fludarabine exposure predicts outcome after CD19 CAR T-cell therapy in children and young adults with acute leukemia	36
Nonrelapse mortality among patients diagnosed with chronic GVHD: an updated analysis from the Chronic GVHD Consortium	36
Altered fibrin clot structure and dysregulated fibrinolysis contribute to thrombosis risk in severe COVID-19	36
Convalescent plasma with a high level of virus-specific antibody effectively neutralizes SARS-CoV-2 variants of concern	36
A case of thrombocytopenia and multiple thromboses after vaccination with ChAdOx1 nCoV-19 against SARS-CoV-2	35
Ixazomib, dexamethasone, and rituximab in treatment-naive patients with Waldenström macroglobulinemia: long-term follow-up	35
Heterogeneous NLRP3 inflammasome signature in circulating myeloid cells as a biomarker of COVID-19 severity	35
INCB84344-201: Ponatinib and steroids in frontline therapy for unfit patients with Ph+ acute lymphoblastic leukemia	35
Primary thromboprophylaxis in ambulatory cancer patients with a high Khorana score: a systematic review and meta-analysis	35
Transcriptomic and genomic heterogeneity in blastic plasmacytoid dendritic cell neoplasms: from ontogeny to oncogenesis	35
Effective bridging therapy can improve CD19 CAR-T outcomes while maintaining safety in patients with large B-cell lymphoma	35
Prognostic impact of the ELN2017 risk classification in patients with AML receiving allogeneic transplantation	34
CRISPR-based screens uncover determinants of immunotherapy response in multiple myeloma	34
Timing of high-dose methotrexate CNS prophylaxis in DLBCL: an analysis of toxicity and impact on R-CHOP delivery	34
Adult cord blood transplant results in comparable overall survival and improved GRFS vs matched related transplant	34
Chromosome 1 abnormalities and survival of patients with multiple myeloma in the era of novel agents	34
Patients with high-risk DLBCL benefit from dose-dense immunochemotherapy combined with early systemic CNS prophylaxis	34
Safety and efficacy of anticoagulant therapy in pediatric catheter-related venous thrombosis (EINSTEIN-Jr CVC-VTE)	34
Caloric and nutrient restriction to augment chemotherapy efficacy for acute lymphoblastic leukemia: the IDEAL trial	34
Exogenous mitochondrial transfer and endogenous mitochondrial fission facilitate AML resistance to OxPhos inhibition	34
Real-world evidence of brexucabtagene autoleucel for the treatment of relapsed or refractory mantle cell lymphoma	34
Haploidentical age-adapted myeloablative transplant and regulatory and effector T cells for acute myeloid leukemia	34
Characteristics and outcomes of KSHV-associated multicentric Castleman disease with or without other KSHV diseases	34
Haploidentical vs sibling, unrelated, or cord blood hematopoietic cell transplantation for acute lymphoblastic leukemia	34
Toxicity and efficacy of CAR T-cell therapy in primary and secondary CNS lymphoma: a meta-analysis of 128 patients	33
Tisagenlecleucel outcomes in relapsed/refractory extramedullary ALL: a Pediatric Real World CAR Consortium Report	33
Sex determines the presentation and outcomes in MPN and is related to sex-specific differences in the mutational burden	33
Eltrombopag for patients with moderate aplastic anemia or uni-lineage cytopenias	33
Midostaurin in patients with acute myeloid leukemia and FLT3-TKD mutations: a subanalysis from the RATIFY trial	33
Late molecular recurrences in patients with chronic myeloid leukemia experiencing treatment-free remission	33
Landscape of driver mutations and their clinical impacts in pediatric B-cell precursor acute lymphoblastic leukemia	33
Impact of ruxolitinib on survival of patients with myelofibrosis in the real world: update of the ERNEST Study	33
Zanubrutinib (BGB-3111) plus obinutuzumab in patients with chronic lymphocytic leukemia and follicular lymphoma	33
Whole-transcriptome analysis in acute lymphoblastic leukemia: a report from the DFCI ALL Consortium Protocol 16-001	33
Suboptimal iron deficiency screening in pregnancy and the impact of socioeconomic status in a high-resource setting	33
Addition of lenalidomide to intensive treatment in younger and middle-aged adults with newly diagnosed AML: the HOVON-SAKK-132 trial	33
Platelet-monocyte interaction amplifies thromboinflammation through tissue factor signaling in COVID-19	32
Overcoming resistance to targeted therapies in chronic lymphocytic leukemia	32
The evolution of factor XI and the kallikrein-kinin system	32
Enrichment of BTK Leu528Trp mutations in patients with CLL on zanubrutinib: potential for pirtobrutinib cross-resistance	32
Health-related quality of life with idecabtagene vicleucel in relapsed and refractory multiple myeloma	32
Clinical implications of sequential MRD monitoring by NGS at 2 time points after chemotherapy in patients with AML	32
Stem cell transplantation for children with hemophagocytic lymphohistiocytosis: results from the HLH-2004 study	32
Polarized mitochondria as guardians of NK cell fitness	32
OvCa-Chip microsystem recreates vascular endothelium–mediated platelet extravasation in ovarian cancer	32
High-dose chemotherapy and autologous stem cell transplant in elderly patients with primary CNS lymphoma: a pilot study	32
Optical genome mapping in acute myeloid leukemia: a multicenter evaluation	32
CD19-positive lymphocyte count is critical for acquisition of anti-SARS-CoV-2 IgG after vaccination in B-cell lymphoma	31
Loss of GPVI and GPIbα contributes to trauma-induced platelet dysfunction in severely injured patients	31